| Literature DB >> 24382976 |
Qi-Long Chen1, Yi-Yu Lu2, Gui-Biao Zhang2, Ya-Nan Song2, Qian-Mei Zhou2, Hui Zhang2, Wei Zhang3, Xin-Sheng Tang4, Shi-Bing Su2.
Abstract
Traditional Chinese medicine (TCM) treatment is regarded as a safe and effective method for many diseases. In this study, the characteristics among excessive, excessive-deficient, and deficient syndromes of Hepatocellular carcinoma (HCC) were studied using miRNA array data. We first calculated the differentially expressed miRNAs based on random module t-test and classified three TCM syndromes of HCC using SVM method. Then, the weighted miRNA-target networks were constructed for different TCM syndromes using predicted miRNA targets. Subsequently, the prioritized target genes of upexpression network of TCM syndromes were analyzed using DAVID online analysis. The results showed that there are distinctly different hierarchical cluster and network structure of TCM syndromes in HCC, but the excessive-deficient combination syndrome is extrinsically close to deficient syndrome. GO and pathway analysis revealed that the molecular mechanisms of excessive-deficient and deficient syndromes of HCC are more complex than excessive syndrome. Furthermore, although excessive-deficient and deficient syndromes have similar complex mechanisms, excessive-deficient syndrome is more involved than deficient syndrome in development of cancer process. This study suggested that miRNAs might be important mediators involved in the changing process from excessive to deficient syndromes and could be potential molecular markers for the diagnosis of TCM syndromes in HCC.Entities:
Year: 2013 PMID: 24382976 PMCID: PMC3870617 DOI: 10.1155/2013/324636
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Differentiation of TCM syndromes in HCC patients.
| Patient | Age | Gender | TCM | TCM |
|---|---|---|---|---|
| HCC 1 | 47 | M | LGDHS | Excessive |
| HCC 2 | 63 | M | LGDHS | Excessive |
| HCC 3 | 61 | F | LGDHS | Excessive |
| HCC 4 | 62 | M | LDSDS | Excessive-deficient |
| HCC 5 | 59 | M | LDSDS | Excessive-deficient |
| HCC 6 | 58 | M | LDSDS | Excessive-deficient |
| HCC 7 | 54 | F | LKYDS | Deficient |
| HCC 8 | 52 | M | LKYDS | Deficient |
| HCC 9 | 42 | M | LKYDS | Deficient |
Figure 1Cluster analysis of differential expression miRNAs in TCM syndromes in HCC. (a) Relationship among three typical syndromes of HCC divided by binary tree classification. (b) Heatmap of differential expressed miRNAs among the LGDHS/normal, LDSDS/normal, and LKYDS/normal.
Figure 2The miRNA-target networks and overlapping miRNA expression in TCM syndromes in HCC. (a) The global profiles of miRNA-target networks in three HCC TCM syndromes. (b) The hub networks of three syndromes from excessive to deficient syndromes. (c) The overlapping miRNA expression levels from the networks of three TCM syndromes.
Figure 3Upexpression miRNA-target networks, GO, and pathway terms in TCM syndromes progression in HCC. (a) Upexpression miRNA-target networks of LGDHS, LDSDS, and LKYDS in HCC. (b) Comparison of GO/pathway terms among the three networks of TCM syndromes. (c) The distribution of overlapping GO terms among the three networks of TCM syndromes. Numbers in the cell represent the number of overlapped GO terms in two networks. Colors were scaled according to the proportion of overlaps.
KEGG and BIOCARTA terms distribution of downregulated genes (upexpression level of miRNAs) of TCM syndromes in HCC.
| Category | Term |
| FDR value |
|---|---|---|---|
| LGDHS | |||
| KEGG | Small cell lung cancer | 0.0159 | 0.0141 |
| LDSDS | |||
| KEGG | Pathways in cancer | 0.0054 | 0.0022 |
| KEGG | Pancreatic cancer | 0.0142 | 0.0043 |
| KEGG | Glioma | 0.0015 | 0.0157 |
| KEGG | Prostate cancer | 0.0036 | 0.0171 |
| KEGG | Small cell lung cancer | 0.0013 | 0.0313 |
| KEGG | Non-small cell lung cancer | 0.0224 | 0.0113 |
| KEGG | Cell cycle | 0.0017 | 0.0156 |
| KEGG | Endocytosis | 0.0110 | 0.0233 |
| KEGG | Focal adhesion | 0.0476 | 0.0436 |
| BIOCARTA | Influence of Ras and Rho proteins on G1 to S transition | 0.0287 | 0.0144 |
| BIOCARTA | Regulation of BAD phosphorylation | 0.0131 | 0.0291 |
| BIOCARTA | Cyclins and cell cycle regulation | 0.0321 | 0.0323 |
| BIOCARTA | Cell cycle:G1/S check point | 0.0471 | 0.0437 |
| LKYDS | |||
| KEGG | Prostate cancer | 0.0048 | 0.0001 |
| KEGG | Pathways in cancer | 0.0001 | 0.0005 |
| KEGG | Glioma | 0.0001 | 0.0011 |
| KEGG | Small cell lung cancer | 0.0015 | 0.0013 |
| KEGG | Melanoma | 0.0019 | 0.0025 |
| KEGG | Non-small-cell lung cancer | 0.0020 | 0.0021 |
| KEGG | Pancreatic cancer | 0.0021 | 0.0022 |
| KEGG | Chronic myeloid leukemia | 0.0072 | 0.0813 |
| KEGG | Apoptosis | 0.0145 | 0.0163 |
| KEGG | Acute myeloid leukemia | 0.0436 | 0.0413 |
| BIOCARTA | Y branching of actin filaments | 0.0066 | 0.0771 |
| BIOCARTA | NFAT and hypertrophy of the heart (transcription in the broken heart) | 0.0108 | 0.0122 |
| BIOCARTA | Influence of Ras and Rho proteins on G1 to S transition | 0.0108 | 0.0122 |
| BIOCARTA | Human cytomegalovirus and map kinase pathways | 0.0136 | 0.0151 |
| BIOCARTA | Overview of telomerase RNA component gene hTerc transcriptional regulation | 0.0257 | 0.0268 |